SEC Form 4 · accession 0001104659-18-018705
Aralez Pharmaceuticals Inc. · ARLZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Kaseta
Officer — Chief Financial Officer
Period of report
Mar 15, 2018
Accepted (ET)
Mar 19, 2018 · 8:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001660719
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, without par valueF1,F2 | Mar 15, 2018 | A | 12,500 | $0.00 | A | 15,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F3 | $1.75 | Mar 15, 2018 | A | 25,000 | A | — | Mar 15, 2028 | Common Shares, without par value | 25,000 | 25,000 | D |
Explanation of responses
- F1Restricted Stock Units granted pursuant to the Aralez Pharmaceuticals Inc. 2016 Amended and Restated Long-Term Incentive Plan, which vest 33.3% annually over three years commencing upon the first anniversary of the date of grant, subject to continued employment or service to the Company.
- F2Includes 833 shares of Common Stock and 14,167 Restricted Stock Units.
- F3The option vests as to 25% of the shares on March 15, 2019, and the remainder vests in substantially equal monthly installments over the 36 months immediately following such date, subject to continued employment or service to the Company.